<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9180">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05703620</url>
  </required_header>
  <id_info>
    <org_study_id>DHC20190025</org_study_id>
    <nct_id>NCT05703620</nct_id>
  </id_info>
  <brief_title>REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions.</brief_title>
  <acronym>RESURRECT</acronym>
  <official_title>REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions - the RESURRECT Trial. A Pilot Proof-of-concept and Safety Study With the Paradise Denervation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Perth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ReCor Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Perth Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The is a non-randomized pilot trial, open-label evaluation of the physiologic response of&#xD;
      native kidney denervation using the Paradise denervation system in CKD, End Stage Renal&#xD;
      Disease (ESRD), and Heart failure (HF)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is unequivocal evidence for an important contribution of increased renal sympathetic&#xD;
      nerve activity to cardiovascular (CV) morbidity and mortality in high risk patient cohorts&#xD;
      with CKD, ESRD and HF. The availability of a highly effective catheter-based ultrasound&#xD;
      device to selectively target renal nerves provides a potential unique opportunity to improve&#xD;
      CV outcomes in these patients, a proposition that now needs to be tested in initial pilot&#xD;
      trials and subsequent appropriately designed randomized controlled trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2021</start_date>
  <completion_date type="Anticipated">May 18, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 18, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in renal sympathetic nerve activity</measure>
    <time_frame>BASELINE TO 3 MONTHS</time_frame>
    <description>Spillover results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in renal sympathetic nerve activity</measure>
    <time_frame>BASELINE TO 12 MONTHS</time_frame>
    <description>Muscle Sympathetic Nerve Activity (MSNA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Baseline to 36 months</time_frame>
    <description>Changes in systolic and diastolic blood pressures</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Heart Failure</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Chronic Kidney Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal Denervation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart Failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal Denervation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>End stage renal disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal Denervation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Denervation</intervention_name>
    <description>All eligible participants receive ultrasound based renal denervation to both kidneys on all eligible vessels</description>
    <arm_group_label>Chronic Kidney Disease</arm_group_label>
    <arm_group_label>End stage renal disease</arm_group_label>
    <arm_group_label>Heart Failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both Male and female patients&#xD;
&#xD;
          -  Ages between 18-75 years of age&#xD;
&#xD;
          -  Individual is competent and willing to provide written, informed consent to&#xD;
             participate in this clinical study with either&#xD;
&#xD;
               -  CKD stage 3a/b or&#xD;
&#xD;
               -  ESRD on stable renal replacement therapy or&#xD;
&#xD;
               -  Mild to moderate heart failure with reduced ejection fraction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ineligible anatomy&#xD;
&#xD;
          -  Prior treatment with other devices for hypertension including but not limited to ROX&#xD;
             Coupler (ROX Medical) , Mobius stent, and/or the CVRx (CVRx Inc) barostimulator&#xD;
             device.&#xD;
&#xD;
          -  Individual has experienced a myocardial infarction, unstable angina, or a&#xD;
             cerebrovascular accident within 3 months of the screening visit.&#xD;
&#xD;
          -  Documented history of chronic active inflammatory bowel disorders such as Crohn's&#xD;
             disease or ulcerative colitis.&#xD;
&#xD;
          -  Individual has clinically significant cardiac structural valvular disease, unless&#xD;
             corrected by a properly functional prosthetic valve&#xD;
&#xD;
          -  Individual has been admitted for inpatient hospitalization for decompensated HF in the&#xD;
             previous month&#xD;
&#xD;
          -  Female participants of childbearing potential must have a negative pregnancy test&#xD;
             prior to treatment.&#xD;
&#xD;
          -  Individual has a known, unresolved history of drug use or alcohol dependency, lacks&#xD;
             the ability to comprehend or follow instructions, or would be unlikely or unable to&#xD;
             comply with study follow-up requirements.&#xD;
&#xD;
          -  Individual is currently enrolled in another investigational drug or device trial.&#xD;
             Note: For the purpose of this protocol, participants involved in extended follow-up&#xD;
             trials for products that were investigational but are currently commercially available&#xD;
             are not considered enrolled in an investigational trial.&#xD;
&#xD;
          -  Individual has a disease or condition (aside from CKD, ESRD, and HFrEF) that may limit&#xD;
             their life expectancy to &lt; 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Schlaich</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Perth Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anu Joyson</last_name>
    <phone>92240390</phone>
    <email>anu.joyson@uwa.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Markus Schlaich</last_name>
    <phone>92240382</phone>
    <email>markus.schlaich@uwa.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anu Joyson</last_name>
      <phone>92240390</phone>
      <email>anu.joyson@uwa.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Markus Schlaich, Prof</last_name>
      <phone>92240382</phone>
      <phone_ext>Schlaich</phone_ext>
      <email>markus.schlaich@uwa.edu.au</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Schlaich, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharad Shetty, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carl Schultz, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 19, 2023</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>January 19, 2023</last_update_submitted>
  <last_update_submitted_qc>January 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Perth Hospital</investigator_affiliation>
    <investigator_full_name>Professor Markus Schlaich</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Renal Denervation</keyword>
  <keyword>Sympathetic Nervous System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

